• Acquisition Expands Drug Discovery Capabilities
    Dr Richard Weaver, Founder & CEO of Xenogesis (right) with Dr Simon Hirst, Founder & CEO of Sygnature

News & Views

Acquisition Expands Drug Discovery Capabilities

Oct 14 2020

With the acquisition of XenoGesis, the UK’s largest independent laboratory-based CRO specialising in pre-clinical DMPK, quantitative bioanalysis, in vitro pharmacology and interpretation, Sygnature has effectively doubled the size of its DMPK department, adding new skills and capabilities to its service offering. Both companies are located at BioCity, Nottingham.

Since its inception in 2011, XenoGesis has achieved a strong track record of success through its focus on high quality science and clinical considerations from the outset of a drug discovery project, resulting in the early prediction of PK and likely human dosage potentially enabling more successful candidate molecules.

Dr Simon Hirst, CEO and Founder at Sygnature, said: “Our ultimate mission at Sygnature is to help create life-changing drugs for patients that have made it through the drug discovery and development process and we recognise the central role that DMPK plays in that journey.

“Sygnature is not growing for the sake of growing. We believe that truly integrated drug discovery is the best possible way forward in bringing novel efficacious drug candidates to man; that having teams working together across every discipline involved in a research project, sharing ideas and resolving challenges, will produce the sparks of innovation and high-quality science needed to enable success.

Dr Richard Weaver, CEO and Founder at XenoGesis added:

“Sygnature and XenoGesis have always had a superb working relationship and been closely aligned in our culture and aspirations. From the start, both companies have focused on world-class science, insightful data interpretation, and creating genuine partnerships with our customers.

“Therefore, this step feels like a very natural one, and we are very excited about what we can accomplish together in helping accelerate our customers’ projects towards the clinic. My team and I are looking forward to joining forces with Sygnature.”

Digital Edition

International Labmate July 2021

July 2021

In This Edition Articles - Deep characterisation and quantitative analysis - Seamless HPLC Method Transfer - How does a sample’s adventure unfold at Diamond? Mass Spectrometry & Spectr...

View all digital editions


InformEx Zone at CPhl North America

Aug 10 2021 Pennsylvania, PA, USA & Online


Aug 18 2021 Beijing, China

DioXin 2021

Aug 22 2021 Xi'an, China

ACS National Meeting & Expo, Fall 2021

Aug 22 2021 Atlanta, GA, USA & Virtual

Microscopy Conference 2021

Aug 22 2021 Digital event

View all events